|
Gene: SOCS7 |
Gene summary for SOCS7 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SOCS7 | Gene ID | 30837 |
Gene name | suppressor of cytokine signaling 7 | |
Gene Alias | NAP4 | |
Cytomap | 17q12 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | O14512 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
30837 | SOCS7 | NAFLD1 | Human | Liver | NAFLD | 7.56e-03 | 2.63e-01 | -0.04 |
30837 | SOCS7 | HCC1_Meng | Human | Liver | HCC | 5.43e-19 | 6.76e-03 | 0.0246 |
30837 | SOCS7 | HCC2_Meng | Human | Liver | HCC | 8.03e-03 | -2.12e-03 | 0.0107 |
30837 | SOCS7 | HCC1 | Human | Liver | HCC | 5.89e-08 | 2.10e+00 | 0.5336 |
30837 | SOCS7 | HCC2 | Human | Liver | HCC | 1.38e-28 | 2.75e+00 | 0.5341 |
30837 | SOCS7 | HCC5 | Human | Liver | HCC | 1.74e-08 | 1.05e+00 | 0.4932 |
30837 | SOCS7 | S014 | Human | Liver | HCC | 4.22e-04 | 1.82e-01 | 0.2254 |
30837 | SOCS7 | S015 | Human | Liver | HCC | 1.40e-03 | 1.86e-01 | 0.2375 |
30837 | SOCS7 | S016 | Human | Liver | HCC | 1.04e-04 | 1.95e-01 | 0.2243 |
30837 | SOCS7 | S028 | Human | Liver | HCC | 6.46e-04 | 2.10e-01 | 0.2503 |
30837 | SOCS7 | S029 | Human | Liver | HCC | 2.42e-02 | 1.56e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00464863 | Liver | NAFLD | glycerolipid metabolic process | 66/1882 | 392/18723 | 1.94e-05 | 5.52e-04 | 66 |
GO:00450174 | Liver | NAFLD | glycerolipid biosynthetic process | 43/1882 | 252/18723 | 3.83e-04 | 5.73e-03 | 43 |
GO:00464742 | Liver | NAFLD | glycerophospholipid biosynthetic process | 33/1882 | 211/18723 | 6.93e-03 | 4.88e-02 | 33 |
GO:00086542 | Liver | HCC | phospholipid biosynthetic process | 150/7958 | 253/18723 | 4.77e-08 | 1.03e-06 | 150 |
GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
GO:004647411 | Liver | HCC | glycerophospholipid biosynthetic process | 121/7958 | 211/18723 | 9.12e-06 | 1.06e-04 | 121 |
GO:0006661 | Liver | HCC | phosphatidylinositol biosynthetic process | 69/7958 | 131/18723 | 1.19e-02 | 4.35e-02 | 69 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04917 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
hsa049171 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SOCS7 | SNV | Missense_Mutation | novel | c.1088G>C | p.Arg363Pro | p.R363P | O14512 | protein_coding | deleterious(0) | possibly_damaging(0.737) | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR |
SOCS7 | SNV | Missense_Mutation | novel | c.1033N>A | p.Pro345Thr | p.P345T | O14512 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.879) | TCGA-D8-A1X9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
SOCS7 | insertion | Frame_Shift_Ins | novel | c.1136_1137insACTTAAGAAACTG | p.Tyr381LysfsTer8 | p.Y381Kfs*8 | O14512 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SOCS7 | insertion | Frame_Shift_Ins | novel | c.1139_1140insTAATTTCAGGATAGTGAGGTTTAAT | p.Tyr381AsnfsTer12 | p.Y381Nfs*12 | O14512 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SOCS7 | SNV | Missense_Mutation | novel | c.1589N>C | p.Val530Ala | p.V530A | O14512 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SOCS7 | SNV | Missense_Mutation | novel | c.1036N>T | p.Pro346Ser | p.P346S | O14512 | protein_coding | tolerated(0.21) | possibly_damaging(0.796) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SOCS7 | SNV | Missense_Mutation | novel | c.1329C>G | p.Ile443Met | p.I443M | O14512 | protein_coding | tolerated(0.07) | possibly_damaging(0.905) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SOCS7 | SNV | Missense_Mutation | novel | c.454C>A | p.Leu152Met | p.L152M | O14512 | protein_coding | deleterious_low_confidence(0.02) | benign(0.367) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SOCS7 | SNV | Missense_Mutation | novel | c.1445N>G | p.Ser482Cys | p.S482C | O14512 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SOCS7 | SNV | Missense_Mutation | novel | c.1591A>G | p.Arg531Gly | p.R531G | O14512 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |